Heart failure: an update from the last years and a look at the near future
Abstract In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clin...
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Wiley
2022-12-01
|
| シリーズ: | ESC Heart Failure |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1002/ehf2.14257 |